Jump to main content.


Notice of Filing a Pesticide Petition to Establish a Tolerance for a Certain Pesticide Chemical in or on Food

Note: EPA no longer updates this information, but it may be useful as a reference or resource.


 [Federal Register: January 5, 2001 (Volume 66, Number 4)]
[Notices]
[Page 1129-1135]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr05ja01-69]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[PF-989; FRL-6761-4]


Notice of Filing a Pesticide Petition to Establish a Tolerance
for a Certain Pesticide Chemical in or on Food

AGENCY:  Environmental Protection Agency (EPA).

ACTION:  Notice.

-----------------------------------------------------------------------

SUMMARY:  This notice announces the initial filing of a pesticide
petition proposing the establishment of regulations for residues of a
certain pesticide chemical in or on various food commodities.

[[Page 1130]]

DATES:  Comments, identified by docket control number PF-989, must be
received on or before February 5, 2001.

ADDRESSES:  Comments may be submitted by mail, electronically, or in
person. Please follow the detailed instructions for each method as
provided in Unit I.C. of the SUPPLEMENTARY INFORMATION. To ensure
proper receipt by EPA, it is imperative that you identify docket
control number PF-989 in the subject line on the first page of your
response.

FOR FURTHER INFORMATION CONTACT:  By mail: Indira Gairola, Registration
Division (7505C), Office of Pesticide Programs, Environmental
Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460;
telephone number: (703) 308-8375; e-mail address:
gairola.indira@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

    You may be affected by this action if you are an agricultural
producer, food manufacturer or pesticide manufacturer. Potentially
affected categories and entities may include, but are not limited to:

------------------------------------------------------------------------
                                                          Examples of
           Categories                 NAICS codes         potentially
                                                      affected  entities
------------------------------------------------------------------------
Industry                          111                 Crop production
                                  112                 Animal production
                                  311                 Food manufacturing
                                  32532               Pesticide
                                                       manufacturing
------------------------------------------------------------------------

    This listing is not intended to be exhaustive, but rather provides
a guide for readers regarding entities likely to be affected by this
action. Other types of entities not listed in the table could also be
affected. The North American Industrial Classification System (NAICS)
codes have been provided to assist you and others in determining
whether or not this action might apply to certain entities. If you have
questions regarding the applicability of this action to a particular
entity, consult the person listed under FOR FURTHER INFORMATION
CONTACT.

B. How Can I Get Additional Information, Including Copies of this
Document and Other Related Documents?

    1. Electronically. You may obtain electronic copies of this
document, and certain other related documents that might be available
electronically, from the EPA Internet Home Page at http://www.epa.gov/.
To access this document, on the Home Page select ``Laws and
Regulations,'' ``Regulations and Proposed Rules,'' and then look up the
entry for this document under the ``Federal Register--Environmental
Documents.'' You can also go directly to the Federal Register listings
at http://www.epa.gov/fedrgstr/.
    2. In person. The Agency has established an official record for
this action under docket control number PF-989. The official record
consists of the documents specifically referenced in this action, any
public comments received during an applicable comment period, and other
information related to this action, including any information claimed
as confidential business information (CBI). This official record
includes the documents that are physically located in the docket, as
well as the documents that are referenced in those documents. The
public version of the official record does not include any information
claimed as CBI. The public version of the official record, which
includes printed, paper versions of any electronic comments submitted
during an applicable comment period, is available for inspection in the
Public Information and Records Integrity Branch (PIRIB), Rm. 119,
Crystal Mall #2, 1921 Jefferson Davis Highway, Arlington, VA, from 8:30
a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The
PIRIB telephone number is (703) 305-5805.

C. How and to Whom Do I Submit Comments?

    You may submit comments through the mail, in person, or
electronically. To ensure proper receipt by EPA, it is imperative that
you identify docket control number PF-989 in the subject line on the
first page of your response.
    1. By mail. Submit your comments to: Public Information and Records
Integrity Branch (PIRIB), Information Resources and Services Division
(7502C), Office of Pesticide Programs (OPP), Environmental Protection
Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460.
    2. In person or by courier. Deliver your comments to: Public
Information and Records Integrity Branch (PIRIB), Information Resources
and Services Division (7502C), Office of Pesticide Programs (OPP),
Environmental Protection Agency, Rm. 119, Crystal Mall #2, 1921
Jefferson Davis Highway, Arlington, VA. The PIRIB is open from 8:30
a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The
PIRIB telephone number is (703) 305-5805.
    3. Electronically. You may submit your comments electronically by
e-mail to: opp-docket@epa.gov, or you can submit a computer disk as
described above. Do not submit any information electronically that you
consider to be CBI. Avoid the use of special characters and any form of
encryption. Electronic submissions will be accepted in Wordperfect 6.1/
8.0 or ASCII file format. All comments in electronic form must be
identified by docket control number PF-989. Electronic comments may
also be filed online at many Federal Depository Libraries.

D. How Should I Handle CBI That I Want to Submit to the Agency?

    Do not submit any information electronically that you consider to
be CBI. You may claim information that you submit to EPA in response to
this document as CBI by marking any part or all of that information as
CBI. Information so marked will not be disclosed except in accordance
with procedures set forth in 40 CFR part 2. In addition to one complete
version of the comment that includes any information claimed as CBI, a
copy of the comment that does not contain the information claimed as
CBI must be submitted for inclusion in the public version of the
official record. Information not marked confidential will be included
in the public version of the official record without prior notice. If
you have any questions about CBI or the procedures for claiming CBI,
please consult the person identified under FOR FURTHER INFORMATION
CONTACT.

E. What Should I Consider as I Prepare My Comments for EPA?

    You may find the following suggestions helpful for preparing your
comments:
    1. Explain your views as clearly as possible.
    2. Describe any assumptions that you used.
    3. Provide copies of any technical information and/or data you used
that support your views.
    4. If you estimate potential burden or costs, explain how you
arrived at the estimate that you provide.
    5. Provide specific examples to illustrate your concerns.
    6. Make sure to submit your comments by the deadline in this
notice.
    7. To ensure proper receipt by EPA, be sure to identify the docket
control number assigned to this action in the subject line on the first
page of your response. You may also provide the

[[Page 1131]]

name, date, and Federal Register citation.

II. What Action is the Agency Taking?

    EPA has received a pesticide petition as follows proposing the
establishment and/or amendment of regulations for residues of a certain
pesticide chemical in or on various food commodities under section 408
of the Federal Food, Drug, and Comestic Act (FFDCA), 21 U.S.C. 346a.
EPA has determined that this petition contains data or information
regarding the elements set forth in section 408(d)(2); however, EPA has
not fully evaluated the sufficiency of the submitted data at this time
or whether the data support granting of the petition. Additional data
may be needed before EPA rules on the petition.

List of Subjects

    Environmental protection, Agricultural commodities, Feed additives,
Food additives, Pesticides and pests, Reporting and recordkeeping
requirements.

    Dated: December 21, 2000.
  James Jones,
Director, Registration Division, Office of Pesticide Programs.

Summary of Petition

    The petitioner summary of the pesticide petition is printed below
as required by section 408(d)(3) of the FFDCA. The summary of the
petition was prepared by the petitioner and represents the view of the
petitioner. EPA is publishing the petition summary verbatim without
editing it in any way. The petition summary announces the availability
of a description of the analytical methods available to EPA for the
detection and measurement of the pesticide chemical residues or an
explanation of why no such method is needed.

Morflex Inc.

PP 8E4966, PP 8E4967

    EPA has received two pesticide petitions (PP 8E4966, PP 8E4967)
from Morflex, Inc., 2110 High Point Road, Greensboro, North Carolina
27403. proposing, pursuant to section 408(d) of the (FFDCA), 21 U.S.C.
346a(d), to amend 40 CFR part 180 to establish an exemption from the
requirement of a tolerance for acetyl tributyl citrate
(Citroflex A4) and triethyl citrate (Citroflex)
when used as inert ingredients in or on growing crops, when applied to
raw agricultural commodities (RAC) after harvest or when applied to
animals (40 CFR 180.1001(c), and (e)). EPA has determined that the
petitions contain data or information regarding the elements set forth
in section 408(d)(2) of the FFDCA; however, EPA has not fully evaluated
the sufficiency of the submitted data at this time or whether the data
support granting of the petitions. Additional data may be needed before
EPA rules on the petitions.

A. Residue Chemistry

    Residue chemistry data are generally not required by EPA regarding
decisions relevant to exemptions from the requirement of a tolerance
for inert ingredient. However, applicable dietary modeling data and
environmental fate data have been completed and is used for the
assessments included in these petitions. Since Morflex is requesting an
exemption from the requirement of a tolerance, an analytical method is
not required.

B. Toxicological Profile

    1. Acute toxicity--i. Oral LD50 in rats. Acetyl tributyl
citrate (ATBC). The acute oral LD50 for ATBC is 31.5 grams/
kilograms body weight (g/kg bwt). Rising doses of ATBC were
administered to groups consisting of 5 rats per group of from 10.5 to
31.5 g/kg bwt. Some animals appeared sluggish, however, they recovered
during the 21-day post dosing observation period. There were no
mortalities at any dose.
    ii. Triethyl citrate (TEC). The acute oral LD50 of TEC
in rats was determined to be 7 milligrams/Liters (mL)/kg bwt. The
technical material triethyl citrate was administered to groups of 5
rats by stomach tube at doses ranging from 5 to 15 mL/kg bwt. Signs of
toxicity occurred within 1-hour and included weakness, depression,
ataxia, hyperexcitability, unrest, urinary incontinence, irregular, and
labored respiration, convulsions preceeding death in some animals.
Mortalities occurred in 2 hours to 3 days, while survivors recovered
within 15 hours to 4 days.
    iii. Oral LD50 in cats--ATBC. The acute oral
LD50 of ATBC was determined to be greater than 50 mL/kg bwt.
The animals showed signs of slight nausea, and within a few hours they
developed a diarrhea with oozing of the oily material from the rectum.
The diarrhea subsided in less than 24 hours. There were no systemic
toxicity signs as judged by the general appearance and behavior of the
animals for periods up to 2 months.
    iv. TEC. The acute oral LD50 of TEC was determined to be
approximately 4 g/kg bwt in cats. TEC was administered by stomach tube
to cats fasted for 24 hours in doses ranging from 1.1 to 10.8 g/kg bwt.
Signs of toxicity consisted of nausea, vomiting, ataxia, weakness,
muscle twitching, tremors, lowered body temperature, gasping, and
shallow respiration, prostration, convulsions, respiratory failure and
death. Mortalities occurred in about 2 hours to 2 days. Animals
surviving recovered within 4 hours to 3 days depending upon the dose
administered. Postmortem examinations showed no abnormalities of the
thoracic abdominal organs related to the toxic signs.
    v. Intraperitoneal LD50 in mice--ATBC. The acute
intraperitoneal LD50 of ATBC was determined to be greater
than 4g/kg bwt in Swiss Albino mice. The animals were observed for
gross effects on appearance and behavior for 72 hours after dosing.
    vi. TEC. The intraperitoneal LD50 of TEC was determined
to be 1.75 g/kg bwt in Swiss Albino mice. Signs of toxicity included
rapid loss of righting reflex without loss of consciousness, increased
respiration rate, and clonic convulsions. Mortalities occurred during
the first hour post dosing.
    vii. Intraperitoneal LD50 in rats. The acute
intraperitoneal LD50 of TEC in rats is 4.2 mL/kg bwt for
females and 4.0 mL/kg bwt for males. Most deaths occurred within one
hour post dosing following a depression of respiration and clonic
convulsions. Pathological examinations of the animals that died
indicated hemorrhage of the lung, pancreas and thymus, and marked
congestion in the kidneys and liver.
    viii. Acute subcutaneous LD50 in rats. The subcutaneous
administration of TEC to rats resulted in LD50 of 6.7 mL/kg
bwt in females and 6.6 mL/kg bwt in males. Mortalities typically
occurred within 24 hours of dosing. Pathological examinations showed
extensive hemorrhage in the lungs, and thymus, loss of hair, edema, and
crust formation at injection sites. In surviving animals, at the end of
the 14-day observation period, necrotic ulcers were noted at injection
sites.
    ix. Acute dermal LD50 in guinea pig and rabbit. The
dermal LD50 of TEC was determined to be greater than 11.4 g/
kg bwt in guinea pigs and greater than 5.7 mg/kg bwt in rabbits.
    x. Acute inhalation LC50 in rats. The 6-hour inhalation
LC50 of TEC in rats was determined to be approximately 1,300
ppm. In this study, groups of rats were exposed to vaporized TEC for 6
hours at concentrations between 1,300 and 3,500 ppm.
    xi. Skin irritation in rabbits--ATBC. ATBC was found to be non-
irritating to rabbit skin when applied as the undiluted technical
material. The abdomens of 3 male Albino rabbits were clipped and 1 mL
of ATBC was applied

[[Page 1132]]

to the intact skin daily for 4 days. The animals were observed for a
period of 36 hours after the last application. There was no evidence of
irritation.
    xii. TEC--TEC was determined to be non-irritating to rabbit skin.
Undiluted TEC was applied to intact or abraded rabbit skin for 24 hours
under occlusion before scoring for irritation.
    xiii. Guinea pig sensitization--ATBC. ATBC was found to be non
sensitizing to the skin of Guinea pigs following the method Magnusson
and Kligman's Guinea pig maximumization test. Sensitization was induced
in guinea pigs by intradermal injections of the test substance and
complete Freunds Adjuvant. The induction process was supplemented 7
days later by application of ATBC to the shoulder injection sites under
occlusion. Fourteen days later the animals were challenged by occluded
patches. Challenges were repeated after 1-week. Evaluations for contact
sensitization were performed at 24 and 48 hours after patch removal.
    xiv. TEC. TEC was found to be a strong sensitizer in 9 of 10 Guinea
pigs after the first challenge and in all 10 Guinea pigs after the
second challenge. TEC was tested for the potential to induce contact
dermatitis according to the Magnusson-Kligman's Guinea pig maximization
test method. Sensitization was induced by intradermal injections of
both test substance and Freunds Adjuvant and the induction process
supplemented 7 days later by the test substance applied to the shoulder
injections sites under occlusion. The animals were challenged by
occluded patch 14 days later.
    xv. Human repeated insult patch test--ATBC. ATBC was evaluated in
59 human subject panelists (males and females) in the repeated insult
patch test of Draize. The test substance was found not to induce dermal
irritation or contact sensitization. For this test, each of the 59
panelists received a test patch (20x20 cm) moistened with 0.4 mL of
ATBC to the upper arms 3 times a week for 3 weeks. Patches were secured
in place for 24 hours before removal. Duplicate challenges were made 2
weeks after the final serial applications, 1 set of patches to original
sites and 1 set to adjacent sites. Patch sites were scored prior to
patch applications and scored at 48 and 96 hours after applications.
    xvi. TEC. Triethyl citrate was tested in an adaptation of the
repeat insult patch test of Draize in 59 human subject panelists (males
and females). A quantity of 0.4 mL of undiluted TEC was applied to each
test patch prior to application. Patches were applied to each panelist
3 times a week for 3 consecutive weeks. Instructions were given to each
panelist to keep the patches dry and to remove them 24 hours after
application. Duplicate challenge applications were made 2 weeks after
the final serial applications; 1 at the original site and 1 at an
adjacent site. The patch sites were evaluated at 48 and 96 hours after
application. There was no evidence of dermal irritation and no
reactions suggestive of contact sensitization in any of the panelists.
    2. Genotoxicty--i. ATBC. Ames Salmonella/microsome reverse mutation
assay. ATBC did not exhibit mutagenic activity in the Ames assay with
or with metabolic activation. ATBC was tested in a preincubation
modification of the Ames assay with Salmonella typhimurium tester
strains TA98, TA100, TA1535, and TA1537. Tests were performed in all
strains, both with and without metabolic activation using S-9 rat liver
systems. Assays were repeated twice in all strains. Another test was
performed with ATBC using Salmonella typhimurium strains TA98, TA100,
TA1535, TA1537 and TA1538, with and without metabolic activation using
rat liver S-9 mix or hamster liver S-9 mix. Results were negative for
mutagenicity in all 5 strains in the presence of both rat and hamster
liver S-9 mix and in the absence of metabolic activation.
    ii. Mouse lymphoma mutagenesis assay. ATBC produced a negative
response in cultures with and without metabolic activation using
Arochlor induced rat liver S-9 mix. The test article was assayed for
mutagenic potential using thymidine kinase locus of L51784 TK+/-mouse
lymphoma cells.
    iii. In vitro chromosomal aberration assay in rat lymphocytes. ATBC
did not exhibit clastogenic activity (increases in chromosomal
aberrations) in cultured rat lymphocytes as compared with negative
controls, either in the presence or absence of metabolic activation.
ATBC was evaluated in a cytogenic assay using rat lymphocyte cells with
and without rat liver S-9 mix metabolic activation. Frequencies of
chromosomal aberrations, based upon mitotic indicies were determined
from ATBC treated cultures and were found not to be significantly
different than negative controls. Based upon the results of this study,
ATBC did not exhibit clastogenic activity in cultured rat lymphocytes.
    iv. Chinese hamster ovary cell/hypoxanthine-guanine-phosphoribosyl
transferase (CHO/HGPRT) forward mutation assay. In this forward
mutation assay, ATBC in 2 independent tests, did not induce a mutagenic
response. ATBC was evaluated both in the absence and presence of rat
liver S-9 mix metabolic activation. The forward mutation frequencies of
ATBC treated cultures were not significantly different from those of
negative controls, indicating no mutagenic response.
    v. Unscheduled DNA synthesis in rats. ATBC did not induce
unscheduled DNA systhesis (UDS) in livers from rats treated with
commercial material at a dose of 10 mL/kg.
    3. Genotoxicity--TEC. Microbial assays, Salmonella typhimurium and
Saccaromyces cerevisiae. TEC was not mutagenic in Salmonella
typhimurium strains TA1535, TA1537, and TA1538 and in Saccharomyces
cerevisiae strain D4, without metabolic activation, and with metabolic
activation using S-9 mix from male mouse, rat and monkey livers. Plate
tests and suspension tests were performed with the indicator strains of
both test organisms. Based upon cell toxicity studies, concentrations
from 0.4 to 1.7% were employed as the dose levels in the mutagenicity
assays. Results were negative for mutagenicity with both bacteria and
yeast organisms, with both the plate and suspension tests, with and
without metabolic activation.
    4. Reproductive and developmental toxicity--i. ATBC. A 2-generation
reproduction study in rats. A 2-generation reproduction study conducted
with ATBC in Sprague Dawley rats resulted in a no observed effect level
(NOEL) of 100 milligrams/kilogram body weight mg/kg bwt/day based upon
the lowest observed effect level (LOEL) of 300 mg/kg bwt/day for
decreased maternal bwts gains and water consumption and reduced bwts
and slightly higher mortalities among their offspring. This 2-
generation reproduction study was conducted in Sprague Dawley rats with
ATBC at dietary levels of 100, 300, or 1,000 mg/kg bwt/day to evaluate
the potential effects on reproductive performance and on the survival
and growth of offspring through 2-generations. In this study, 4 groups
of male and female rats received control or 1 of the 3 dietary levels
of ATBC continuously. Prior to mating, males were treated for 77 days
and females for 21 days. After mating, males of the F0
generation were removed and pregnant females were continued on diet
through gestation, delivery and lactation. Subsequent F1
offspring were maintained on the same diets as their parents for at
least 10 weeks prior to mating within groups. The resulting
F2 generation litters were also maintained on the same diets
as their parents for at least 14 days.
    ii. TEC. Developmental toxicity in the developing chicken embryo.
Treatment

[[Page 1133]]

of chicken embryos with TEC resulted in a negative teratogenic
response. In this study, TEC was dissolved in ethanol to deliver a
maximum of 10 mg per egg. The test substance in solution was
administered by 2 routes, into the yolk and through the air sac. For
each route, eggs were treated at 2 stages of incubation: preincubation
(0-hour), and at the fourth day (96- hour).
    5. Subchronic toxicity--i. ATBC. Fourteen-day range finding dietary
toxicity in rats. In a 14-day range finding feeding study with ATBC,
the NOEL was determined to 1,000 mg/kg bwt/day. In this study ATBC was
administered in the diet at concentrations of 1%, 2.5% and 5%
equivalent to doses of 1,000, 2,700 and 5,000 mg/kg bwt/day.
Observations included clinical signs of toxicity, bwts, food intake,
test substance intake, complete gross pathology including organ
weights, and histopathologic examinations of livers. Food intake was
initially decreased in all test groups, however, differences persisted
in only among males of the 5,000 mg/kg bwt/day group. The initial
differences are likely related to the unpalatability of the diet. Body
weights were significantly lower among animals of the 2,700 mg/kg bwt/
day and 5,000 mg/kg bwt/day treatment groups throughout the study.
Organ weight determinations resulted in significantly increased
relative liver weights among high dose females. Upon microscopic
examinations of the livers there were increased cytoplasmic
eosinophilia and a concomitant reduction of glycogen content of
hepatocytes in periportal areas from animals of the 2,700 mg/kg bwt/day
and 5,000 mg/kg bwt/day dose groups.
    ii. Ninety-day dietary toxicity in rats. The results of a 90-day
feeding study with ATBC resulted in a NOEL of 300 mg/kg bwt/day based
upon the LOEL of 1,000 mg/kg bwt/day for minor changes is relative
liver weights, liver enzymes and bilirubin levels. This study was
conducted Sprague Dawley rats receiving dietary levels of ATBC of 0,
100, 300, or 1,000 mg/kg bwt/day for 90 days. All animals were observed
daily for clinical signs of toxicity. Ophthalmoscopic observations were
conducted in all animals of the highest dose group at pretest, and just
prior to the treatment period. Body weights were recorded daily for all
animals on day 1 of treatment and weekly thereafter. Food consumption
was measured over 1 week periods, while water consumption was measured
in each animal during the first and eleventh week of dosing. The
results of clinical chemistries, hematology and urinalysis were
recorded and complete necropsies with histological examinations were
performed. A few statistically significant differences were noted
between animals of the high dose group (1,000 mg/kg bwt/day) and
controls including increased relative liver weights, liver enzymes, and
bilirubin levels. However, there were no histopathological findings
indicative of treatment related effects.
    iii. TEC. Subchronic oral toxicity in mice. TEC was evaluated for
subchronic toxicity in a group of 20 mice receiving 350 mg/kg bwt/day
of commercial grade test substance (purity >99%) in 3% acacia
intraperitoneally, daily for 14 consecutive days. A control group
consisting of the same number of mice received 3% acacia daily under
the same schedule. Body weight gains of TEC treated mice were
significantly lower as compared with controls by day 7. There were no
significant differences in red and white blood cell counts, clotting
times, and hemoglobin levels between treated and control mice. Under
the conditions of the study, the LOEL was established at 350 mg/kg bwt/
day, when given intraperitoneally for 14 days.
    iv. Subchronic dietary toxicity in rats. In an 8 week dietary
feeding study in rats with TEC, the NOEL was established at 4 g/kg bwt/
day. Groups of approximately 4 males and 4 females were administered
TEC in the diet at concentrations of 0, 0.5, 1.0, or 2.0%. These
dietary concentrations were estimated to be equivalent to 0, 1, 2, or 4
g/kg bwt/day TEC. TEC administered daily in the diet at doses up to
approximately 1/2 of the rat oral LD50 had no significant
effect on growth. Blood counts including red and white blood cell
counts, differential cell counts were not significantly among treatment
and control groups. There were no, gross findings in thoracic or
abdominal organs at necropsy. Histological sections of organs,
including the heart, lungs, gastrointestinal tract, liver, pancreas,
spleen, and kidneys, revealed no differences between treatment and
control animals.
    v. Subchronic toxicity in dogs. In this study, 4 dogs were given
daily doses of 2.5 to 3.5 mL/kg bwt/day (2,840 to 3,975 mg/kg bwt/day)
as rising doses for 7 to 12 weeks. The study report indicates bwt gains
were normal as were results of urinalysis and serum chemistries.
Hematology results suggested a tendency to anemia. Organ weights were
normal except for one abnormally heavy liver. At these doses severe and
widespread liver pathology was evident. Other organs were reportedly
normal. As the purpose of the study was to determine the toxic dose for
repeated administrations of TEC, the NOEL was not established.
    6. Chronic toxicity--i. ATBC. 2-year chronic toxicity in rats. A 2-
year chronic toxicity study conducted with ATBC in Sherman rats at
dietary concentrations of 0, 200, 2,000, or 20,000 ppm (equivalent to
0, 10, 100, or 1,000 mg/kg bwt/day) resulted in a NOEL of 1,000 mg/kg
bwt/day. Animals were observed for physical appearance and behavior
throughout the study as were individual bwts. All animals that died and
those sacrificed at the end of the study were examined for gross and
histological changes. No differences in behavior or physical appearance
was noted among treated and control animals. There were no
statistically significant differences between the growth of animals
treated with ATBC and controls. There were no statistical differences
in mortalities among treatment and control animals. Inflammatory
disease of the lungs was the most common finding at autopsy, however,
there was no treatment related differences. There were no differences
in tumor frequencies among treatment and control animals. There was no
reported evidence of effects on the endocrine system.
    ii. TEC. 2-year chronic dietary toxicity in rats. In this study,
TEC administered to rats for 2 years via dietary administration
resulted in no significant effects at the highest dose tested,
equivalent to 1,500 mg/kg bwt/day. Sprague Dawely rats (15 per sex per
dose group) were fed diets containing TEC at concentrations of 0, 0.33,
1.0, or 3.0% for 2 years. These dietary concentrations are estimated to
be equivalent to 0, 165, 500, or 1,500 mg/kg bwt/day. Clinical
observations were made daily and individual bwts were measured weekly.
Blood and urine evaluations were conducted at specified intervals.
Scheduled interim sacrifices of animals included macroscopic
examinations of thoracic and abdominal organs and microscopic
examinations of the kidney and liver tissues. All animals that died
spontaneously during the study, as well as all animals remaining at the
termination of study (1 or 2 years), were examined by a pathologist. At
terminal sacrifice, microscopic examinations were made of kidney,
liver, heart, lungs, spleen, stomach, small intestine, adrenals,
ovaries, uterus, testes, and seminal vesicles. There were transiently
lower bwts among males of the high dose group animals, possibly related
to the unpaletibility of the diet. There were no significant
differences observed between treated and control groups for the

[[Page 1134]]

following blood examinations: hemoglobin, erythrocyte count, non-
protein nitrogen, and sugar determination. Urine tests for reaction,
albumin, reducing substances, and microscopic evaluation were all
considered to be normal. Terminal and interim autopsies disclosed no
findings that were significant or attributable to TEC treatment. Size
and weight of organs of the principal tissues at the time of autopsy
were unremarkable. There were no significant differences between
treated and control animals in comparison to the pathological findings.
    iii. Six months dietary toxicity in dogs. In a 6 month dietary
toxicity study in dogs, TEC did not exhibit any toxic effects and the
NOEL is greater than 280 mg/kg bwt/day the highest dose tested (HDT).
Groups of 4 Beagle or Beagle type dogs (males and females) were
administered 6 days per week for 6 months at dietary levels of TEC
equivalent to 55 or 280 mg/kg bwt/day. The dogs were observed daily,
weighed weekly and urinalysis were conducted at 3 and 6 months after
initiation of the study. Blood samples were taken at 2, 4, and 6 months
after initiation of dosing for hematological examinations. Dogs were
sacrificed at the end of the in-life dosing phase and necropsied. Body
weight gain and clinical observations were normal throughout the study.
No significant changes or abnormalities were reported in hematology,
serum chemistry or urinalysis during the course of the study. Gross
examinations of major organs and organ weights at necropsy were normal.
Histopathologic examinations of the major organs did not show any
abnormalities.
    7.  Animal metabolism--i. ATBC. Metabolism and disposition of
acetyl tributyl citrate in male Sprague Dawley rats. The metabolism of
ATBC using \14\C-ATBC in rats receiving single oral doses of 70 mg/kg.
ATBC was determined to be rapidly absorbed and excreted with an
elimination half-life of 3.4 hours. Greater than 98% of administered
\14\C was achieved via urine, feces and in expired air 48 hours after
dosing. Urinary metabolites identified in this study include acetyl
citrate, monobutyl citrate, acetyl monobutyl citrate, dibutyl citrate,
and acetyl dibutyl citrate.
    ii. Metabolism of acetyltributylcitrate (ATBC) and tributylcitrate
(TBC) in human serum and rat liver homogenates. The metabolism of ATBC
and the intermediate deacetylated metabolite tributylcitrate (TEC), was
studied in vitro using human serum and rat liver homogenates. At a
concentration of 100 g/mL in human serum, ATBC was found to
undergo extensive metabolism with a half-life of approximately 32
hours. Also, at a concentration of 100 g/mL in rat liver
homogenate, ATBC was found to undergo extensive and complete metabolism
with a half-life of approximately 10 minutes. There is very little or
no emonstrable TBC in the 2 test systems because of the rapid further
metabolism of this intermediate metabolite. The metabolic half-life of
TBC in human serum and rat liver homogenate was approximately 4 hours
and a few seconds, respectively. These studies confirm the ready and
complete conversion of ATBC and TBC via ester hydrolysis to acetic
acid, citric acid and butanol. Butanol would be expected to undergo
oxidation to butyric acid and further metabolism by b-oxidation.
    iii. TEC. Absorption, distribution, metabolism and excretion of
tiethyl citrate in the rat. Following a single oral 2 mg/kg dose of
\14\C-TEC in rats, a peak blood concentration of about 1.48 g
eq./g blood was achieved at 15 minutes post-administration, blood
concentration rapidly decreased to about 0.05 g eq./gm blood
after 1 hour and was barely detectable after 24 hours. Tissue
distribution was examined after single oral administration of a 2 mg/kg
dose of \14\C-TEC to rats. At 15 minutes post-administration,
relatively high \14\C concentrations were found in the didney (37.81+
5.02 g eq./g tissue), stomach (10.00+ 3.53 g eq./g
tissue), small intestines including contents (10.65 + 3.15 g
eq./g tissue) and liver (4.40 + 0.77 g eq./g tissue). By 24
hours after dosing, the \14\C concentrations detected in most tissues
had decreased to near the detection limit (0.01 g eq./g
tissue), with the exception of the large intestine including contents.
Cumulative urinary, fecal and expiratory excretions of \14\C-TEC were
93, 0.2 and 1%, respectively, 8 hours after administration of a single
2 mg/kg dose of \14\C-TEC. At 120 hours after dosing, the total \14\C
excretion of urine, feces and expiration had reached 99%. Metabolism of
\14\C-TEC was investigated using the 24-hour urine of rats after a
single oral administration of a 2 mg/kg dose. Three major metabolites
were separated by thin-layer chromatography and identified using gas
chromatography (GC/MS). Two of the metabolites were isomers of diethyl
citrate and 1 was found to be monoethyl citrate.
    8. Endocrine disruption. Chronic and reproductive toxicity data
conducted with ATBC and chronic toxicity data conducted with TEC are
without adverse effects to reproductive or the endocrine system. Also,
the compounds do not share structural similarities with currently known
or chemicals suspected to have endocrine disruptive properties.

C. Aggregate Exposure

    1. Dietary exposure--i. Food. ATBC and TEC are currently classified
as generally recognized as safe (GRAS) for use in foods and food
packaging, cosmetics, pharmaceuticals, and as plasticizers for consumer
and packaging products. The current petition, requests the exemption
from tolerances for these compounds when used as inert ingredients in
agricultural formulations for use on growing crops for post harvest
applications to food crops and applications to animals. Although
residue data are generally not required for inert ingredient exemptions
from tolerances, Morflex, Inc. has developed worst case assumptions
using Novigen Sciences Dietary Exposure Evaluation Model (DEEM) with
data inputs based upon the model of Kenaga and Hoergers: Maximum
Expected Residues on Vegetation. The Kenega nomogram is used to predict
maximum residue levels present on day 0 following different application
rates of a chemical to 1 of 6 different categories of plants or plant
parts. The 3 basic features of the Kenaga nomogram-catagories of plants
and plant parts, maximum predicted residue levels, and a linear dose-
residue relationship. Crops and crop groups selected for this analysis
include the following: leafy vegetables (succulent or dried), fruiting
vegetables, cucurbit vegetables, citrus fruits, pome fruits, stone
fruits, berries, cereal grains, grapes, and bananas. The reference dose
chosen for this analysis, was derived from the NOEL resulting from a
chronic rat (2-year) study conducted with ATBC. This study was
conducted at dietary concentrations of 0, 200, 2,000, and 20,000 ppm
equivelant to 0, 10, 100, and 1,000 mg/kg bwt/day of ATBC. No effects
were reported up to the HDT. Therefore, for the purposes of this
assessment, a chronic reference dose (RfD) of 10 mg/kg bwt/day was
used. The chronic RfD includes an uncertainty factor of 100 to account
for intra-species and inter-species variations. Food consumption data
from the United States Department of Agriculture (USDA) CSFII conducted
in 1994 through 1996, were used to estimate dietary exposure. The
levels of ATBC and TEC can vary depending upon the percent of ATBC and
TEC in the formulation and/or the application rate of the product. For
purposes of this screening level assessment, an application rate of 3
pounds per acre of ATBC or TEC was assumed. Also, no adjustment was
made for percent crop

[[Page 1135]]

treated and all commodities contain residues at predicted day zero
levels. For this screening level assessment with an application rate of
3 pounds ATBC or TEC per acre, the following 0-time level residues are
predicted from the nomogram: leafy vegetables-375 ppm, legume
vegetables-36 ppm, fruiting vegetables, cucurbit vegetables, citrus
fruits, pome fruits, stone fruits, berries, cereal grains, grapes, and
bananas-21 ppm.. Using the above modeling parameters, chronic exposure
was estimated for the overall U.S. population and 25 population
subgroups. Chronic exposure for the overall U.S. population was
estimated to be 0.492873 mg/kg bwt/day, representing 4.9% of the RfD.
The exposure estimate for the most highly exposed population subgroup,
children 1-6 years of age, was 0.984312 mg/kg bwt/day, or 9.8%.
    ii. Drinking water. Based upon the chemical and physical
properties, and the environmental fate characteristics, ATBC and TEC
are not expected to persist environmentally, nor result in significant
concentrations in drinking water sources.
    2. Non-dietary exposure. ATBC and TEC are currently used in non-
food use pesticide formulations, as well as in food, food packaging,
cosmetics, medical devices and pharmaceuticals, and as plasticizers.

D. Cumulative Effects

    Cumulative effects are not expected since ATBC and TEC are rapidly
degraded to natural substances.

E. Safety Determination

    1. U.S. population. Based upon the dietary residue exposure
analysis using the Kenega nomogram, the most sensitive population,
children 1-6 years, was 0.984312 mg/kg bwt/day or 9.8% of the RfD for
the crops and crop groups used in this assessment. Results of a 2-
generation reproduction study with ATBC did not reveal developmental or
reproduction effects at doses up to 100 mg/kg bwt/day. Also, based on
the absence of pup toxicity up to the dose level (1,000 mg/kg bwt/day)
producing maternal effects, there is no evidence of special post-natal
sensitivity to infants and children. It is concluded that there is
reasonable certainty that no harm will result to infants and children
from aggregate exposure to acetyl tributyl citrate (ATBC) or triethyl
citrate (TEC) when used as inert ingredients in agricultural
formulations of pesticides.
    2. Infants and children. No embryotoxic, developmental, or
teratogenic effects have been associated with acetyltributyl citrate
(ATBC) or triethyl citrate (TEC).

F. International Tolerances

    Morflex Inc. is unaware of any International tolerances or CODEX
maximum residue limits (MRL's) for acetyltributyl citrate (ATBC) or
triethyl citrate (TEC) on any crop or livestock commodities.
[FR Doc. 01-369 Filed 1-4-01; 8:45 am]
BILLING CODE 6560-50-S 

Local Navigation


Jump to main content.